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A clinical trial was performed to evaluate 3BNC117, a potent anti–HIV-1 antibody, in infected individuals during suppressive 
antiretroviral therapy and subsequent analytical treatment interruption (ATI). The circulating reservoir was evaluated by 
quantitative and qualitative viral outgrowth assay (Q2VOA) at entry and after 6 mo. There were no significant quantitative 
changes in the size of the reservoir before ATI, and the composition of circulating reservoir clones varied in a manner that 
did not correlate with 3BNC117 sensitivity. 3BNC117 binding site amino acid variants found in rebound viruses preexisted in 
the latent reservoir. However, only 3 of 217 rebound viruses were identical to 868 latent viruses isolated by Q2VOA and near 
full-length sequencing. Instead, 63% of the rebound viruses appeared to be recombinants, even in individuals with 3BNC117-
resistant reservoir viruses. In conclusion, viruses emerging during ATI in individuals treated with 3BNC117 are not the 
dominant species found in the circulating latent reservoir, but frequently appear to represent recombinants of latent viruses.
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Introduction
Small-molecule antiretroviral drugs are highly effective in sup-
pressing HIV-1 viremia. However, therapy needs to be lifelong 
because it fails to eliminate a reservoir of latent HIV-1 viruses 
integrated into the genome of infected cells (Chun et al., 1997; 
Finzi et al., 1997). Significant efforts are currently focused on 
therapies, including immunotherapies, to target the reservoir 
to achieve sustainable antiretroviral therapy (ART)-free re-
mission (Churchill et al., 2016; Martin and Siliciano, 2016).
The immunotherapeutic agents that are clinically most 
advanced in this respect are newly discovered broad and po-
tent monoclonal antibodies (broadly neutralizing antibodies 
[bNAbs]) that recognize the HIV-1 envelope protein expressed 
on the surface of infected cells and virions (Halper-Stromberg 
and Nussenzweig, 2016). These new antibodies protect 
against and suppress infection in mice and macaques (Klein 
et al., 2012; Barouch et al., 2013; Horwitz et al., 2013; Shingai 
et al., 2013, 2014; Halper-Stromberg et al., 2014; Gautam et 
al., 2016). In human clinical trials, they suppress viremia 
and delay viral rebound in the setting of treatment interrup-
tion (Caskey et al., 2015, 2017; Lynch et al., 2015; Bar et al., 
2016; Scheid et al., 2016). Most importantly, immunother-
apy differs from small-molecule drugs in that antibodies can 
eliminate circulating virus and infected cells through Fc-me-
diated effector mechanisms (Igarashi et al., 1999; Halper-
Stromberg et al., 2014; Lu et al., 2016; Horwitz et al., 2017). 
In addition, bNAb administration is associated with develop-
ment of  potent antiviral CD8+ T cell immunity in macaques 
(Nishimura et al., 2017).
Infusion of VRC01, an anti–CD4 binding site antibody, in 
the setting of continued ART did not measurably alter the size 
of the latent reservoir in six individuals (Lynch et al., 2015). 
However, the sensitivity of  circulating reservoir viruses to 
VRC01 was not determined, and the relationship of latent vi-
ruses to plasma viruses that emerge during an analytical treat-
ment interruption (ATI) was not examined.
Here we evaluate the effects of 3BNC117, a broad and potent 
anti–CD4 binding site bNAb (Scheid et al., 2011, 2016; Caskey et 
al., 2015), in the setting of continued ART administration and 
during treatment interruption. We report on the dynamics of 
resistant and sensitive viruses in the latent HIV reservoir over 
a 6-mo period before ATI, and the relationship between latent 
and rebound viruses.
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Results
Study participants
15 HIV-1–infected participants virologically suppressed on ART 
were enrolled and underwent ATI (Table 1, Table S1, and Fig. S1). 
Participants received four intravenous infusions of 3BNC117 at 
30 mg/kg at week 0, week 12, week 24, and week 27 (Fig. 1 A). 
Leukapheresis was performed at week −2 and week 23 to col-
lect peripheral blood mononuclear cells (PBMCs) for analyses 
of the latent reservoir. ART was discontinued 2 d after the week 
24 infusion. To evaluate the effects of 3BNC117 on viruses with 
a range of neutralization sensitivities, participants were not 
screened for 3BNC117 sensitivity before enrollment. All partici-
pants had a viral load of less than 50 copies/ml at day 0. The me-
dian baseline CD4+ T cell count was 688 cells/mm3, with a range 
of 391–1,418 cells/mm3. Most participants entered the study on 
a nonnucleoside reverse-transcriptase inhibitor (NNR TI)-based 
ART regimen. Consistent with prior observations, 10 of the 15 
participants (67%) had baseline bulk outgrowth culture viruses 
with 3BNC117 IC50 titers <2.0 µg/ml (Table S1; Scheid et al., 2016; 
Cohen et al., 2018).
Safety and pharmacokinetics
Infusions of 3BNC117 were generally well tolerated. One serious 
adverse event deemed not related to 3BNC117 occurred in a partic-
ipant who required hospitalization for a psychotic episode asso-
ciated with a new diagnosis of bipolar disorder. This participant 
was subsequently removed from the study before entering the ATI 
phase. 14 of the 15 participants who completed the study received 
all four infusions of 3BNC117. One participant received only three 
infusions because viral load results demonstrating viral rebound 
were available before the fourth infusion. 29 adverse events were 
considered at least possibly related to 3BNC117. Among these, three 
were graded as moderate and one was graded as severe. Complete 
data on adverse events is provided in Table S2. In many partici-
pants, CD4+ T cell counts transiently declined during the ATI pe-
riod (Table S3). The adverse event profile observed here is similar 
to what has been reported in prior trials with 3BNC117 (Caskey et 
al., 2015; Scheid et al., 2016). The average half-life of 3BNC117 was 
14.7 d, slightly shorter than the half-life of 17 d in HIV-uninfected 
individuals, but very similar to that previously reported for in-
dividuals receiving ART (Caskey et al., 2015; Scheid et al., 2016).
Size of the latent reservoir
The quantitative and qualitative viral outgrowth assay (Q2VOA) 
was used to examine the effect of 3BNC117 on the latent reser-
voir (Lorenzi et al., 2016). CD4+ T lymphocytes were collected by 
leukapheresis at weeks −2 and 23, during which time the partic-
ipants remained on suppressive ART and received two infusions 
of 3BNC117 at weeks 0 and 12, maintaining detectable 3BNC117 
serum levels for most of the 23-wk period. Q2VOA was performed 
for 10 participants: the first nine to enter the ATI phase of the 
trial (with the exception of participant 604, whose virus could 
not be grown in Q2VOA) and participant 616. Nine of these par-
ticipants had samples available from both week −2 and week 23 
(participant 609 declined the week 23 leukapheresis).
The infectious units per million (IUPM) of latently infected 
CD4+ T cells among these nine participants at weeks −2 and 23 
ranged from 0.33 to 1.9 and 0.47 to 4.0, respectively. We found 
no significant changes in IUPM between the two time points for 
any participant (defined by a more than sixfold change; Crooks 
et al., 2015; Fig. 1 B). We conclude that two doses of 3BNC117 ad-
ministered over 23 wk in the setting of suppressive ART does not 
measurably reduce the size of the latent reservoir.
The latent reservoir is dynamic over a 6-mo period
To examine the molecular nature of the replication-compe-
tent viruses in the latent reservoir, we sequenced env from la-
tent viruses isolated by Q2VOA at weeks −2 and 23. An average 
of 1.18 × 108 CD4+ T lymphocytes were cultured per participant 
per time point, yielding an average of 40 independent env se-
quences per participant per time point (Table S4). Phylogenetic 
analysis showed that each participant analyzed was infected 
with epidemiologically unrelated clade B viruses (Fig. S2). The 
clonal structure of the latent reservoir differed among the par-
ticipants analyzed and could be divided into three categories: 
dominated by a single clone (603, 610, and 616); dominated by 
multiple clones (601, 602, 605, 611, and 613); or nonclonal (608; 
Fig. 1 C). Overall, 57% of viral sequences in the reservoir were 
clonal, which is consistent with previous studies (Lorenzi et al., 
2016; Bui et al., 2017; Hosmane et al., 2017; Lee et al., 2017).
When comparing the two time points, we observed clonal 
fluctuations that varied from appearance or disappearance of 
clones to large alterations in their relative size. For example, a 
clone from participant 602 comprised 11% of the circulating res-
Table 1. Characteristics of participants at baseline (n = 15)
Characteristics
Male sex - n (%) 14 (93)
Median age (range) 43 (26–58)
Race or ethnicity
White non-Hispanic 5
Black non-Hispanic 6
Hispanic, regardless of race 3
Multiple, non-Hispanic 1
HIV RNA <50 copies/ml (day 0) – n (%) 15 (100)
CD4 T cell count – cells/mm3
Median (range) 688 (391–1,418)
Nadir CD4 T cell count – cells/mm3
Median (range) 350 (250-500)
Years since starting ART
Median (range) 11 (1-21)
Years on uninterrupted ART
Median (range) 7 (2-16)
ART regimen – n (%)
Integrase inhibitor based 5 (33)
Protease inhibitor based 2 (13)
NNR TI based 8 (53)
3BNC117 IC50 <2.0 µg/ml – n (%) 10 (67)
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ervoir at week −2 but 42% of the circulating reservoir at week 23 
(Fig. 1 C). These differences could not be ascribed to variability in 
the assay, as determined by independently repeating the analysis 
on samples from five individuals (Fig. S3). Using the Q2VOA data 
and Bayesian inference, we inferred the IUPM of each clone at 
each time point. In five of the nine participants, there were statis-
tically significant fluctuations within the circulating reservoir, 
indicating that the observed changes in the composition of the 
reservoir between the two time points was very unlikely to be the 
result of finite sampling alone (Fig. 1 D). However, these fluctu-
Figure 1. Changes in the circulating latent reservoir before treatment interruption. (A) Study design; blue arrows represent 3BNC117 infusions. (B) 
Change in IUPM of HIV-1 between week −2 and week 23, as determined by Q2VOA. There were no significant changes in IUPM between these two time points 
for any participant (defined by a more than sixfold change; Crooks et al., 2015). (C) Pie charts depicting the distribution of culture-derived env sequences from 
the two time points. The number in the inner circle indicates the total number of env sequences analyzed. White represents sequences isolated only once across 
both time points (singles), and colored areas represent identical sequences that appear more than once (clones). The size of the pie slice is proportional to the 
size of the clone. Red arrows denote clones that change in size between the two time points. These data include a second set of independent experiments that 
were performed for five participants to confirm reproducibility (Fig. S3). (D) Fluctuations within the latent reservoirs of each participant. Changes are measured 
in log2 fold change of IUPM between week −2 and week 23. Full bars represent clones, and empty bars represent all singles as one group. P values from Fisher’s 
exact test (two-sided) are shown for participants with significant changes between the two time points. ***, P < 0.001; *, P < 0.05. Colored boxes below each 
bar represent the 3BNC117 IC50 titer of the particular clone. NT, not tested.
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ations were not correlated with the sensitivity of the outgrown 
viruses to 3BNC117, with some resistant clones decreasing in size 
and some sensitive clones increasing in size (Fig. 1 D). We con-
clude that the size of latent reservoir clones in circulation fluc-
tuates over a 6-mo interval in individuals treated with 3BNC117 
while on suppressive ART, and that this effect is independent of 
bNAb sensitivity.
3BNC117 delays viral rebound in sensitive participants
Participants received two additional doses of 3BNC117 2 d be-
fore and 3 wk after ART interruption (Fig. 1 A). Viral rebound 
occurred between 2 and 17 wk thereafter (Fig. S4). The average 
time to rebound was 5.5 wk, which was a significant delay com-
pared with historical controls (P < 0.0001; Fig. 2 A). The size of 
the latent reservoir, as determined by Q2VOA at week 23, did not 
correlate with time to rebound (Fig. 2 B).
To determine whether there was a correlation between the 
antibody sensitivity of the latent reservoir and time to rebound, 
we examined the antibody sensitivity of Q2VOA-derived viruses. 
For many participants, latent viruses exhibited a range of sensi-
tivities to 3BNC117 and other bNAbs that target distinct epitopes 
(Lorenzi et al., 2016; Tables S5 and S6). For example, viruses ob-
tained by Q2VOA for participant 601 ranged from sensitive (IC50 
= 1.45 µg/ml) to completely resistant to 3BNC117 (IC50 > 50 µg/
ml; Fig. 2 C, blue circles). Participant 616, who demonstrated the 
longest delay in time to rebound, harbored a reservoir that was 
both highly sensitive and of restricted neutralization diversity 
(Fig. 2 C). The 3BNC117 IC50 titer of the most resistant latent virus 
isolated from each of these participants correlated with time to 
rebound (P = 0.04, R2 = 0.44; Fig. 2 D). Overall, individuals with 
latent viruses that were resistant (IC50 > 2.0 µg/ml) had an aver-
age time to rebound of 3.6 wk, while those with sensitive viruses 
had an average time to rebound of 9.2 wk (Fig. 2, E and F). Thus, 
preexisting resistance within the latent reservoir is predictive 
of bNAb efficacy.
To assess the neutralization sensitivity of rebound viruses, 
single genome analysis (SGA) was performed on plasma, and 
outgrowth cultures were performed using PBMCs obtained at the 
time of rebound. For seven participants, outgrown viruses from 
the time of rebound were identical or highly similar to plasma 
SGA viruses (Dataset S1). Thus, the viruses isolated from re-
bounding cells are often similar to those isolated by plasma SGA.
Neutralization titers were determined for the viruses isolated 
from PBMC cultures (Cohen et al., 2018). Overall, the 3BNC117 
IC50 titers measured on the rebound viruses were similar to 
those found among the corresponding individual’s latent viruses 
(Fig. 2 C, red circles). We conclude that the circulating latent vi-
ruses isolated by Q2VOA are representative of the overall neutral-
ization profile present within the latent reservoir.
Rebound and latent viruses are distinct
Plasma rebound viruses isolated by SGA were compared with 
Q2VOA-derived latent viruses. Participants harboring resistant 
latent viruses demonstrated polyclonal rebound, while partici-
Figure 2. Time to rebound following treatment interruption. (A) Kaplan–Meier plot comparing viral rebound in 52 historical controls who underwent ATI 
without antibody treatment (black), and the 15 participants (red) who underwent ATI with 3BNC117 infusions. Y axis indicates percentage of participants with 
viral loads below 200 RNA copies/ml, x axis indicates weeks after ATI. The P value is based on the log-rank test (two-sided). (B) Dot plot representing the rela-
tionship between IUPM at week 23 and time to rebound for all participants for whom Q2VOA was performed. The P value was calculated using the Spearman 
correlation (two sided). (C) Dot plot representing the 3BNC117 sensitivities of latent and rebound viruses. Q2VOA-derived latent viruses are shown as blue 
circles, and culture-derived rebound viruses as red circles. Culture-derived rebound viruses could not be obtained from participants 611, 613, and 616. (D) Dot 
plot representing the correlation between 3BNC117 sensitivity of the most resistant virus isolated by Q2VOA and week of rebound. The P value was calculated 
using the Spearman correlation (two-sided). (E) Kaplan–Meier plot comparing viral rebound in 52 historical controls (black), and five participants (red) whose 
latent reservoirs were found to contain viruses resistant to 3BNC117 (IC50 > 2.0 µg/ml) by Q2VOA. (F) Kaplan–Meier plot comparing viral rebound in 52 histor-
ical controls (black), and five participants (red) whose latent reservoirs were found to only contain viruses sensitive to 3BNC117 (IC50 ≤ 2.0 µg/ml) by Q2VOA.
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pants with sensitive latent viruses had restricted rebound diver-
sity, as previously observed (Scheid et al., 2016; Fig. 3). Although 
some rebound viruses were closely related to reservoir viruses, 
only 3 of 217 rebound env sequences were identical to the 768 
Q2VOA-derived latent viruses isolated from nine participants 
(Fig. 3 and Dataset S2). Moreover, the three exceptions were all 
found in a single individual (participant 602) and represented 
only 9.7% of all rebound sequences isolated from that participant 
(Fig. 3). Although the majority of analyzed participants harbored 
reservoirs dominated by expanded clones, these clones did not 
emerge in plasma upon treatment interruption. Strikingly, even a 
latent expanded clone with complete resistance to 3BNC117 could 
not be found among rebound viruses (Fig. 3, participant 601).
3BNC117 resistance mutations in the latent reservoir
We compared the sequences of putative 3BNC117 target sites in 
env obtained from plasma rebound viruses to Q2VOA-derived se-
quences from the circulating reservoir for the presence of mu-
tations (Caskey et al., 2015; Lynch et al., 2015; Bar et al., 2016; 
Scheid et al., 2016; Cheng et al., 2018). Despite the lack of overlap 
between the rebound and latent viruses noted above, rebound 
viruses demonstrated nucleotide and corresponding amino acid 
variants in the 3BNC117 binding site that preexisted in the latent 
reservoir. These variants were often present at low frequencies 
in the reservoir and enriched in rebound viruses (Fig.  4, red 
arrows). For example, all rebound sequences from participant 
601 contain an isoleucine at position 459, compared with 33% 
of sequences within the latent reservoir. In participant 609, all 
rebound sequences at position 371 contain a leucine, which is 
present in just a small minority of latent reservoir sequences. 
On the other hand, there were only five cases in which amino 
acid variants found in the majority of rebound sequences were 
not detected in the latent reservoir (Fig. 4, black arrows). We con-
clude that while latent and rebound viruses are distinct, 3BNC117 
binding site variants present in rebound viruses are frequently 
preexisting within the observed latent reservoir.
Relationship between rebound viruses and 
circulating latent viruses
Despite the fact that 3BNC117 binding site variant amino acids 
found in rebound sequences were already present within the la-
tent reservoir, identical reservoir and rebound sequences were 
Figure 3. Phylogenetic trees of latent and rebound env sequences. Maximum likelihood phylogenetic trees of env sequences of viruses isolated from 
Q2VOA outgrowth cultures and rebound SGA. Four participants with varying 3BNC117 sensitivity, clonal structure, and diversity are shown. Participants are 
categorized as 3BNC117 resistant or sensitive based on the presence of any resistant (IC50 > 2.0 µg/ml) viruses within the reservoir. Q2VOA-derived viruses 
from week −2 are represented as empty black rectangles; viruses from week 23 as full black rectangles; and rebound SGA viruses as red rectangles. Asterisks 
indicate nodes with significant bootstrap values (bootstrap support ≥90%). Clones are denoted by colored rectangles beside the phylogenetic tree. These colors 
correspond to colors in the pie charts in Fig. 1 C. Numbers represent 3BNC117 IC50 neutralization titers. For rebound viruses, neutralization values shown were 
determined from culture-derived viruses that were identical or highly similar to the particular SGA viruses.
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exceedingly rare. While occasional rebound viruses were very 
similar to latent viruses, the average Hamming distance between 
rebound and latent sequences among all participants was 31 nu-
cleotides, excluding insertions and deletions.
Because Q2VOA is limited by its dependence on reactivation 
of latent viruses in vitro (Ho et al., 2013; Bruner et al., 2016; 
Hosmane et al., 2017), we also examined latent viruses by a re-
activation-independent method. Near full-length HIV genome 
analysis (Ho et al., 2013; Bruner et al., 2016) was performed on 
week 23 samples for participants with Q2VOA viruses that dis-
played varying sensitivity, phylogenetic diversity, and clonal 
structure. Between 9 and 33 near full-length sequences were ob-
tained from each of six participants, for a total of 133 sequences. 
For participants 603 and 616, whose reservoirs were dominated 
by a large clone, 85% of near full-length env genes were iden-
tical to Q2VOA-derived viruses. For the other four participants, 
the identity between near full-length sequences and Q2VOA-de-
rived viruses ranged from 8.6% to 47.3% (Table S4). However, we 
found no instance of identical near full-length HIV sequences 
and rebound viruses among the five participants for whom re-
bound SGA sequences were available (Dataset S3). The average 
Hamming distance between env genes from near full-length HIV 
sequences and rebound viruses was 32 nucleotides, excluding 
insertions and deletions, which is similar to that for Q2VOA-de-
rived sequences. We conclude that intact proviral DNA sequences 
obtained from circulating CD4+ T cells overlap with sequences 
obtained by Q2VOA but differ from sequences obtained from re-
bound plasma SGA.
To examine the accumulation of mutations during ATI as a 
potential explanation for the divergence between latent and 
Figure 4. Amino acid variants at 3BNC117 binding sites in latent and rebound viruses. Chart illustrates amino acid changes in and around known 3BNC117 
contact residues in Env (amino acid positions 274–283, 364–374, and 455–471), according to HXB2 numbering. Plus symbols represent 3BNC117 contact sites 
confirmed by crystal structures. Q2 indicates latent viruses isolated by Q2VOA, and RB represents rebound viruses isolated by SGA. Each amino acid is rep-
resented by a color, and the frequency of each amino acid is indicated by the height of the rectangle. Red arrows represent instances in which an amino acid 
found at low frequency in latent viruses became a majority amino acid in rebound viruses, and black arrows represent instances in which a majority rebound 
virus amino acid variant was not found among latent viruses.
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rebound viruses, we created a mathematical model to simulate 
this process (Fig. S5). For each participant, we computed the 
frequency of mutations accumulated during the simulated re-
bound, where the time to rebound in simulation was within 1 
wk before or after the observed time to rebound for that partic-
ipant (Fig. 5 A, gray bars). Using this model and including 868 
env sequences from both near full-length sequencing and Q2VOA 
(Fig. 5 A, blue bars), we found only seven rebound sequences that 
were within the number of expected mutations, and all of these 
were found in participant 602.
To examine the possibility that rebound viruses are related to 
latent viruses by recombination, we analyzed latent and rebound 
sequences using the 3SEQ recombination algorithm (Boni, 2018). 
We found statistical evidence of recombination (rejection of the 
null hypothesis of clonal evolution) among rebound viruses for 
seven of the nine participants tested (Table S7). In the majority of 
recombination events, the two “parent” sequences derived from 
the latent reservoir, and the “child” sequence was a rebound se-
quence; however, there were instances in which the parents were 
comprised of either a latent and rebound sequence or two rebound 
sequences (Table S8). We also found evidence of recombination 
among latent sequences, as might be expected considering that the 
reservoir is established during periods of viremia (Table S9). Ex-
amples of recombinant rebound viruses are illustrated in Fig. 5 B. 
Of note, there was only a single instance among the 27 latent par-
ents involved in rebound virus recombination events in which the 
latent virus was an expanded clone. In this case (participant 613), 
the rebound virus that derived from this recombination event ac-
counted for only 1 out of the 12 rebound viruses isolated. The other 
11 rebound viruses derived from a recombination event between 
two latent viruses that were “singles” (Dataset S3 and Tables S8 
and S10). Taking into account the possibility of recombination, the 
observed distance between latent and rebound viruses decreases 
and is often close to the range predicted by the mutation simula-
tion model described above (Fig. 5 A, yellow bars). We conclude 
that in addition to the accumulation of mutations during ATI, re-
combination may account for the considerable genetic distance 
between circulating latent and rebound viruses.
Discussion
We studied 15 HIV-1–infected individuals who received two doses 
of monoclonal antibody 3BNC117 over a 23-wk period while on 
suppressive ART. A third dose was administered 2 d before ART 
interruption, and a fourth 3 wk after ATI.
As expected, administration of 3BNC117 did not alter the size 
of the circulating reservoir in the setting of suppressive ART 
(Lynch et al., 2015). We found that the composition of the circu-
lating latent reservoir varied significantly over the 23-wk period 
before ATI, and the observed fluctuations were independent of 
the sensitivity of the latent viruses to 3BNC117. In addition, the 
neutralization profile obtained from the reservoir by Q2VOA is 
predictive of time to rebound, and rebound virus amino acid 
variants are frequently preexisting within the latent reservoir. 
Finally, although the rebounding viruses are typically absent 
from the circulating latent reservoir, the sequences of rebound 
viruses frequently correspond to latent virus recombinants.
Antibody monotherapy in the absence of ART delays viral re-
bound and selects for antibody-resistant viruses (Caskey et al., 
2015, 2017; Scheid et al., 2016). In a previous study, participants 
prescreened for 3BNC117 sensitivity by bulk culture who received 
infusions of 3BNC117 at time 0 and 3 wk demonstrated an average 
delay in rebound of 6.7 wk (Scheid et al., 2016). The same regimen 
was administered in the setting of the ATI in the current study, 
but in participants who were not prescreened for sensitivity. Ret-
rospective analysis by Q2VOA revealed that resistant participants 
rebounded after 3.5 wk, which is similar to historical controls. In 
contrast, rebound was delayed for an average of 9.2 wk in par-
ticipants whose reservoirs were found to harbor only sensitive 
viruses. Thus, although the outgrown viruses obtained by Q2VOA 
do not appear in the rebound, their neutralization profile is rep-
resentative of the clinically relevant latent reservoir.
The size of the latent reservoir remains relatively constant 
over time, with a calculated half-life of 3.6 yr (Finzi et al., 1999; 
Crooks et al., 2015). Nevertheless, the reservoir is dynamic, as 
established by the discovery of clones of T cells bearing repli-
cation-competent integrated viruses that expand and contract 
over a period of years (Cohn et al., 2015; Wang et al., 2018). 
While bNAbs have been shown to clear infected cells (Igarashi 
et al., 1999; Halper-Stromberg et al., 2014; Lu et al., 2016), nei-
ther 3BNC117 nor VRC01 (Lynch et al., 2015) altered the size of 
the HIV reservoir when administered during suppressive ART, 
possibly due to the limited expression of viral env in this setting. 
However, there was significant fluctuation in the distribution of 
circulating clones of CD4+ T cells containing latent viruses over 
the 6-mo period before ART interruption that was not directly 
related to 3BNC117 sensitivity. These changes could be due to 
homeostatic proliferation, stimulation by cognate antigen, or 
cell death. For example, an influenza-specific CD4+ T cell clone 
that harbors a latent virus might expand after vaccination or 
exposure to the pathogen, and later contract. Alternatively, the 
observed differences could simply be due to changes in the spe-
cific T cell clones that happen to be in circulation at the two time 
points. Our finding that the distribution of circulating clones of 
latent cells can change dramatically in a relatively short period of 
6 mo indicates that the circulating reservoir is far more dynamic 
than previously appreciated.
Viral outgrowth cultures using PBMCs are limited in that they 
only capture the circulating fraction of the reservoir that can be 
reactivated in vitro. Nevertheless, even with limited sampling, 
there was a 48.7% overall overlap between 133 near full-length 
provirus sequences amplified from DNA and 513 sequences ob-
tained from Q2VOA in six participants (Table S4 and Dataset S3). 
Thus, there is good concordance between the near full-length 
DNA assay and Q2VOA.
Although we obtained an average of 80 latent HIV-1 sequences 
for each participant, we found only three instances in which the 
rebounding virus was identical to a latent virus. However, the 
neutralization sensitivity of isolated latent viruses correlated 
with time to rebound, and 3BNC117 binding site nucleotide and 
amino acid variants found in rebound sequences were frequently 
preexisting in the latent reservoir. The observations that latent 
viruses are distinct from rebound viruses, but that latent viruses 
are phenotypically and genotypically predictive of rebound vi-
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Figure 5. Relationship between latent and rebound sequences. (A) Histograms show the percentage of env sequences (y axis) and nucleotide distance (x 
axis). The blue bars represent the observed Hamming distance between rebound and latent viruses. The gray bars represent the predicted distance between 
rebound and latent viruses based on a simulation of mutation accumulation during the ATI period for each participant. The yellow bars represent the minimal 
possible distance between the rebound and latent viruses including the possibility of recombination. (B) Examples of putative recombination events. Parent 
env sequences are represented in red or blue and child sequences in combined red and blue. LR denotes latent reservoir sequences, and RB denotes rebound 
sequences. The recombination breakpoints shown are the midpoints of the ranges determined by the 3SEQ algorithm (Table S8). White lines represent point 
mutations unique to the child sequence. Parent and child sequences shown here are marked with green and red stars, respectively, in the phylogenetic 
trees in Dataset S3.
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ruses, appear to be at odds but can be reconciled at least in part 
if rebound viruses in fact derive from latent viruses as a result 
of recombination.
Recombination is a major source of HIV-1 diversity (Robertson 
et al., 1995; Burke, 1997). Recombination occurs when two RNA 
strands from different viruses coinfect a single cell, or when a 
virus enters a cell that is transcribing a provirus. Recombinant 
genomes are generated by reverse transcription template switch-
ing. HIV-1 recombination rates have been estimated at ∼1.4 × 10−5 
to 1.38 × 10−4 events per base per generation (Shriner et al., 2004; 
Neher and Leitner, 2010; Batorsky et al., 2011). This rate is within 
range of that of reported HIV mutation rates (Roberts et al., 1988; 
Ji and Loeb, 1992; Abram et al., 2010). Recombination has been 
found to mediate escape from ART (Kellam and Larder, 1995; 
Moutouh et al., 1996), CD8+ T cells (Streeck et al., 2008; Ritchie 
et al., 2014), and autologous neutralizing antibodies (Chaillon et 
al., 2013; Moore et al., 2013; Song et al., 2018).
By incorporating the possibility of recombination and es-
timating the number of mutations that might have occurred 
during the ATI period for each participant, 63% or 137 of 217 re-
bounding viruses could have derived from the observed latent 
reservoir. This includes five of nine individuals in which all or 
nearly all of the rebound viruses could be accounted for by this 
approach. Thus, in 56% of the individuals studied, latent viruses 
detected by Q2VOA or near full-length genome sequencing ap-
peared to have contributed genetic information to the viruses 
that emerge at the time of rebound.
Recombinants were found in 3BNC117-sensitive participants 
and also in the participant with complete resistance to 3BNC117 
(608), and therefore these events do not appear to be dependent 
on bNAb administration. While expanded clones comprised 57% 
of all outgrowth sequences, in only a single instance did a parent 
recombinant sequence come from an expanded latent clone. In 
all other instances, the parents in the recombination events were 
viruses that were isolated only once across the two time points.
The dearth of expanded clones as parents in recombination 
events might be explained if expanded T cell clones harbor vi-
ruses with reduced fitness. Alternatively, there may be differ-
ences in reactivation requirements of latent viruses in vivo and 
in vitro, such that latent viruses in large clones are readily re-
activated in vitro but are resistant to reactivation in vivo. The 
latter would be consistent with the ability of the clones to expand 
without undergoing apoptosis or pyroptosis, as typically happens 
during productive infection (Wang et al., 2018). Among other 
possibilities, resistance to reactivation in vivo could be related to 
provirus integration in a transcriptionally silent site. Differences 
between in vitro and in vivo reactivation may also partially ex-
plain why we did not find any correlation between IUPM values 
and time to rebound. Other potential explanations for this find-
ing include the limited range of IUPM values observed, and the 
fact that IUPM values from outgrowth culture are not predictive 
of the size of the reservoir as determined by the number of intact 
sequences (Ho et al., 2013). Finally, the number of recombina-
tion events observed likely represents an underestimate since we 
only considered recombination events within env.
It has been suggested that recombination may be important 
for the survival of reactivated latent viruses because latent vi-
ruses are simply less fit (de Verneuil et al., 2018) or more sensi-
tive to the host immune responses (Immonen et al., 2015). While 
our findings suggest that recombination does in fact confer a 
fitness advantage, our data do not allow us to determine when 
recombination occurred. If the recombinants are preexisting but 
not detected in circulation before the rebound, it would imply 
that they are extremely rare in circulation. This remains an im-
portant consideration, because although we cultured an average 
of 2.36 × 108 CD4+ T lymphocytes per participant, the number of 
latent cells sampled represents only a small fraction of the total 
reservoir. Alternatively, rebound viruses may be emerging from 
a tissue-resident noncirculating cellular compartment such as 
those described for tissue-resident effector memory T cells in 
lymphoid or gut tissue (Mueller and Mackay, 2016). This might 
imply that such cells have a unique propensity to reactivate their 
latent viruses. If, on the other hand, recombination does occur at 
the time of rebound, it may have significant implications for un-
derstanding the emergence of viral rebound and the frequency 
with which latent viruses are reactivated.
In conclusion, by examining the effects of antibody therapy 
on the circulating latent reservoir, we document its dynamic na-
ture and its relationship to viruses that emerge upon interrup-
tion of ART in individuals receiving 3BNC117.
Materials and methods
Study design
An open-label study was conducted in HIV-infected partic-
ipants virologically suppressed on ART (clinicaltrials.gov, 
NCT02588586). Study participants were enrolled sequentially 
according to eligibility criteria. All participants provided written 
informed consent, and the study was conducted in accordance 
with International Conference on Harmonization Good Clinical 
Practice guidelines. The study protocol was approved by the In-
stitutional Review Boards at the Rockefeller University and Weill 
Cornell Medical Center. Participants were followed for a total of 
60 wk from the time of enrollment. The primary outcome mea-
sures of the study were safety and the time to virologic rebound 
after ART interruption.
Study participants
Study participants were recruited at The Rockefeller University 
Hospital and Weill Cornell Medical Center Clinical Trials Unit, 
both in New York. All infusions were performed at The Rockefel-
ler University Hospital. Eligible participants were HIV-infected 
adults on ART aged 18–65 yr with plasma HIV-1 RNA <50 cop-
ies/ml for 12 mo before enrollment, <20 copies/ml at the time of 
screening, and CD4 count >500/µl. Exclusion criteria included 
hepatitis B or C infection, history of AIDS-defining illness within 1 
yr before enrollment, CD4 nadir <200/µl, and significant medical 
conditions or laboratory abnormalities. Participants on an NNR 
TI were switched to an integrase inhibitor–based regimen 4 wk 
before treatment interruption to avoid monotherapy as a result 
of the prolonged half-life of NNR TIs. Time to viral rebound was 
compared with a historical cohort of 52 participants who under-
went ATI without intervention in trials performed by the AIDS 
Clinical Trials Group, as previously described (Scheid et al., 2016).
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Study procedures
The appropriate volume of 3BNC117 was calculated according to 
body weight, diluted in sterile normal saline to a total volume of 
250 ml, and administered intravenously over 60 min. Study par-
ticipants received 30 mg/kg of 3BNC117 on weeks 0, 12, 24, and 
27 and remained under monitoring at The Rockefeller Univer-
sity Hospital for 4 h after each infusion. Participants returned for 
frequent follow-up visits for safety assessments, which included 
physical examination and measurement of clinical laboratory 
parameters such as hematology, chemistries, urinalysis, and 
pregnancy tests (for women). Leukapheresis was performed at 
The Rockefeller University Hospital at week −2 and week 23. ART 
treatment was interrupted 2 d after the third 3BNC117 infusion 
(week 24). ART was reinitiated after two consecutive plasma viral 
load measurements exceeded 200 copies/ml or CD4 counts fell 
below 350/µl. Plasma HIV-1 RNA levels were monitored weekly 
during the ATI period, and CD4 counts were measured every 
other week. Study investigators evaluated and graded adverse 
events according to the DAI DS AE Grading Table v.2.0 and de-
termined causality. The CTC AE v.4.03 grading scale was used for 
reporting and grading adverse events related to infusion reac-
tions. Blood samples were collected before and at multiple times 
after 3BNC117 infusion. Samples were processed within 4 h of 
collection, and serum and plasma samples were stored at −80°C. 
PBMCs were isolated by density gradient centrifugation. The ab-
solute number of PBMCs was determined by an automated cell 
counter (Vi-Cell XR; Beckman Coulter), and cells were cryopre-
served in FBS plus 10% DMSO.
Q2VOA
Q2VOA was performed using PBMCs isolated by leukapheresis, 
as previously described (Lorenzi et al., 2016). Q2VOA isolates 
replication-competent viruses from the latent reservoir using a 
limiting dilution method such that each virus likely originates 
from a single reactivated infectious provirus. The frequency of 
latently infected cells was calculated using the IUP MStats v.1.0 
(Rosenbloom et al., 2015; Rosenbloom and Elliott, 2018).
Viral neutralization testing by TZM.bl neutralization assay
Supernatants from p24-positive Q2VOA wells were tested against 
a panel of bNAbs by the TZM.bl neutralization assay, as described 
(Li et al., 2005; Montefiori, 2005). Neutralization assays were 
conducted in a laboratory meeting Good Clinical Laboratory 
Practice (GCLP) Quality Assurance criteria (Michael S. Seaman, 
Beth Israel Deaconess Medical Center, Boston, MA).
Measurement of 3BNC117 serum levels by TZM.bl 
neutralization assay
Serum concentrations of 3BNC117 were measured at multiple 
time points postinfusion using a validated luciferase-based 
neutralization assay in TZM.bl cells as previously described 
(Sarzotti-Kelsoe et al., 2014). Briefly, serum samples were tested 
using a primary 1:20 dilution with fivefold titration series against 
HIV-1 Env pseudovirus Q769.d22, which is highly sensitive to 
neutralization by 3BNC117. Env pseudoviruses were produced 
using an ART-resistant backbone vector that reduces background 
inhibitory activity of antiretroviral drugs if present in the serum 
sample (SG3ΔEnv/K101P.Q148H.Y181C, M.S. Seaman, unpub-
lished data). 3BNC117 clinical drug product was also tested in 
every assay setup using a primary concentration of 10 µg/ml with 
fivefold titration series. The serum concentration of 3BNC117 for 
each sample was calculated as follows: serum ID50 titer (dilution) 
× 3BNC117 IC50 titer (μg/ml) = serum concentration of 3BNC117 
(μg/ml). Murine leukemia virus was used as a negative control. 
All assays were performed in a laboratory meeting GCLP stan-
dards. The half-life of 3BNC117 was calculated using Phoenix 
WinNonLin Build 8 (Certara).
Bulk cultures
We performed bulk viral outgrowth cultures using PBMCs 
harvested at week −2, and from rebound samples as described 
(Caskey et al., 2015). Sequence analysis on bulk culture viruses 
was performed as previously described (Lorenzi et al., 2016).
SGA of plasma rebound virus env genes
SGA and sequencing of HIV-1 env genes was performed as previ-
ously described (Salazar-Gonzalez et al., 2008; Scheid et al., 2016; 
Caskey et al., 2017).
Q2VOA-derived virus sequence analysis
HIV env sequences from p24-positive supernatants were ob-
tained and analyzed as previously described (Lorenzi et al., 
2016). Sequences derived from each independent Q2VOA well 
with double peaks (cutoff consensus identity for any residue 
<75%), stop codons, or shorter than the expected envelope sizes 
were omitted from downstream analysis. Phylogenetic analysis 
was performed by generating nucleotide alignments using MAF 
FT (Katoh and Standley, 2013) and posterior phylogenetic trees 
using PhyML v3.1 (Guindon et al., 2010), using the GTR model 
with 1,000 bootstraps.
Near full-length genome analysis
Genomic DNA was extracted from 1–10 × 106 CD4+ T cells from 
week 23 leukapheresis samples. DNA was subjected to limit-
ing-dilution PCR using seminested primers in the gag gene 3Gag-
ININ 5′-GGG GCT GTT GGC TCT GGT-3′ (Ho et al., 2013; Bruner et 
al., 2016). PCR products were visualized and quantified using 1% 
96-well E-Gels (Invitrogen). DNA dilutions in which <30% of the 
gag PCR wells were positive were selected for further analysis be-
cause they have a >90% of probability of containing a single copy 
of HIV DNA in each PCR reaction based on the Poisson distribu-
tion. Near full-length outer PCR was performed, and 1-µl aliquots 
were subjected to nested env PCR (Li et al., 2007; Ho et al., 2013). 
Samples containing ∼2,600 bp env amplicons were subjected to 
four-segment PCR (A, B, C, D; Ho et al., 2013). Samples containing 
segment A+C, A+D, B+C, or B+D were subjected to library prepa-
ration and sequencing (Lorenzi et al., 2016). Sequence adapters 
were removed using Cutadapt v.1.9.1, and read assembly for each 
virus was performed in three steps: (1) de novo assembly was per-
formed using Spades v.3.9.0 to yield long contig files; (2) contigs 
longer than 255 bp were aligned to an HIV full genome reference 
sequence, and a consensus sequence was generated using Mira 
assembly v.4.0.2; and (3) reads were realigned to the consensus 
sequence to close gaps, and a final read consensus was generated 
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for each sequence. Sequences with double peaks (cutoff consen-
sus identity for any residue <75%), stop codons, or shorter than 
the expected near full-genome size were omitted from down-
stream analyses.
3BNC117 binding site analysis
All env sequences were translated to amino acids and aligned 
using ClustalW (Larkin et al., 2007). The HXB2 (K03455) env se-
quence was used as a reference for numbering the amino acids. 
Frequency plots were produced for each env position targeted by 
3BNC117 (Zhou et al., 2013).
Clonal fluctuation calculation
Clonal composition shifts between time points in individual par-
ticipants. We employed a statistical test to gauge whether such 
changes in composition could be explained by finite sampling 
alone, or whether they indicated real changes in the relative 
proportions of each clone in the reservoir. For this analysis, the 
counts for all sequences that were only observed once across time 
points were merged together in a group of “singles.” All other se-
quence counts were considered separately. We used Fisher’s exact 
test, implemented in R, to determine whether the counts of each 
clone (including the singles) observed at each time point were 
consistent with a single underlying distribution for both time 
points. IUPM were inferred for each clone based on the particular 
Q2VOA run from which each member of the clone was isolated, 
as previously described (Lorenzi et al., 2016). Bayesian Markov 
chain Monte Carlo was implemented in Stan, using four separate 
chains of 105 iterations. The first 50,000 iterations for each chain 
were discarded as warm-up.
Simulation of mutation accumulation during rebound
Rebounding viral sequences were rarely identical to those ob-
served in viral outgrowth assays or by near full-length sequenc-
ing. To understand whether the differences between rebound 
sequences and those in the observed reservoir might be at-
tributed to mutations accumulated during the rebound process, 
or whether the rebound virus was instead likely to have origi-
nated from clones that were not previously observed, we devel-
oped a stochastic mutation simulation model.
The model is based on that of Hill et al. (2014). We began with 
a population of 106 latently infected cells. Latent viruses can re-
activate with rate A, in which case the latently infected cell be-
comes actively infected. The product of these two parameters 
(the number of latently infected cells and the reactivation rate) 
gives the approximate number of reactivation events per day. 
Actively infected cells die with rate d, without infecting other 
cells, or burst with rate b. In the latter case, the actively infected 
cell also dies, but the release of virions results in the active in-
fection of c new cells. During each burst event, the number of 
new infected cells c is assumed to follow a Poisson distribution. In 
principle, latently infected cells could also die or homeostatically 
expand, but we assumed that such processes typically occur at 
much slower rates than the fast replication dynamics of actively 
infected cells. Therefore, they are not expected to contribute 
substantially to the rebound process, so we did not include these 
possibilities in our simulation.
The underlying parameters (reactivation rate, death rate of 
actively infected cells, etc.) are not perfectly constrained by ex-
periment and may vary between individuals. Following the ap-
proach of Hill et al. (2014), we therefore chose the net growth rate 
of rebound virus, the ratio of the variance to the mean number 
of new infected cells during a cell bursting event, and the rate 
of reactivation of latently infected cells to be random within the 
bounds of experimental constraints (see Hill et al., 2014 for fur-
ther details). In addition to these parameters, we also allowed the 
net death rate of actively infected cells to vary, which was not 
included in the analysis of Hill et al. (2014). We used the results 
of Markowitz et al. (2003) to constrain the death rate of infected 
cells, which was estimated to be ∼1 d−1 with a standard devia-
tion of 0.3 d−1.
In addition to this simple model tracking the number of latent 
and actively infected cells, we also considered evolution of the 
virus at the sequence level. To compare with the data obtained 
in this study, we assumed a sequence length for Env of 2,600 bp. 
We are specifically interested in the accumulation of de novo 
mutations during the rebound process. We therefore treated the 
length 2,600 sequences as binary, where zeros represent nucle-
otides that are the same as the source sequence from the latent 
reservoir and ones represent a mutation. This approximation 
is justified because the number of mutations observed is much 
smaller than the length of the sequence, and thus the probabil-
ity of back mutations is very small. We assumed that mutations 
occur during the reverse transcription process, when new in-
fection events occur after an actively infected cell bursts. The 
probability of mutation per site per new infection event is 3 × 
10−5 (Sanjuán et al., 2010). In addition, we allowed for the possi-
bility of recombination between sequences, with a probability of 
crossover between strands of 1.4 × 10−5 per site per new infection 
event (Neher and Leitner, 2010). This probability also implicitly 
includes the probability of coinfection of a single host cell.
For simplicity, we assumed that mutations have no effect on 
the fitness (or replication rate) of the virus. However, it is known 
that nonsynonymous mutations are often strongly deleterious, 
including in HIV (Loeb et al., 1989; Haddox et al., 2016; Zanini et 
al., 2017; Louie et al., 2018). Thus, our assumption of neutrality 
likely overestimates the true number of mutations that would be 
accumulated during the rebound process.
We simulated this stochastic rebound process until either the 
number of actively infected cells reaches 3 × 105, corresponding 
roughly to a threshold of detection for virus in the blood of ∼200 
copies ml−1 (Hill et al., 2014), or until the total simulation time 
reaches 100 d. We repeated these simulations using 104 random 
sets of parameters as described above. Different parameter choices 
and stochastic effects led to a range of observed rebound times 
(Fig. S5). At the end of each simulation, we also recorded the dis-
tribution of the number of mutations accumulated during the re-
bound process. As expected, the average number of accumulated 
mutations in the rebound sequences increased with the rebound 
time, though there was substantial stochastic variation (Fig. S5).
Distance, recombination snippet
To conservatively estimate the true distance (in terms of number 
of mutations) between rebound sequences and those in the res-
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ervoir, we counted each observed variant in rebound sequences 
as a mutation only if it did not match with any of the nucleotides 
at that site in the observed reservoir sequences. This prevents 
us from computing spuriously large mutational distances simply 
due to recombination between diverse sequences in the reservoir 
during the rebound process. The estimated rate of recombina-
tion in HIV is high, comparable to the mutation rate (Neher and 
Leitner, 2010), and thus the possibility of recombination cannot 
be simply neglected. Indeed, tests for signatures of recombina-
tion (Lam et al., 2018) in the rebound sequences found multiple 
likely recombination events for all patients in this study except 
for 603 and 610.
Code availability
Code used for these simulations is available on GitHub 
(Barton, 2017).
Data availability
Sequence data that support the findings of this study have 
been deposited in GenBank with the accession codes KY113410–
KY113436, MG196371–MG196394, MG196444–MG196489, 
MH262588–MH262721, and MH262722–MH263643.
Online supplemental material
Fig. S1 shows the participant flow diagram. Fig. S2 shows a phy-
logenetic tree with all env sequences from all participants. Fig. 
S3 shows clone frequency in repeat Q2VOA experiments. Fig. S4 
shows plasma viral loads and 3BNC117 levels for individual par-
ticipants. Fig. S5 shows typical time to rebound and accumulated 
mutations in simulations. Dataset S1 shows a phylogenetic tree 
of env sequences from rebound outgrowth culture and rebound 
SGA. Dataset S2 shows a phylogenetic tree of env sequences from 
Q2VOA and rebound SGA. Dataset S3 shows a phylogenetic tree of 
env sequences from Q2VOA, near full-length, and rebound SGA. 
Table S1 shows the clinical characteristics of individual partici-
pants. Table S2 shows adverse events. Table S3 shows laboratory 
values and 3BNC117 concentrations. Table S4 shows a summary 
of the number of sequences obtained. Table S5 shows IC50 titers 
of viruses for 3BNC117. Table S6 shows IC50 titers of viruses for 
other bNAbs. Table S7 shows P values from the 3SEQ recombina-
tion algorithm for rebound viruses. Table S8 shows output from 
the 3SEQ recombination algorithm. Table S9 shows P values from 
the 3SEQ recombination algorithm for latent viruses. Table S10 
shows the latent parents viruses among rebound recombinants.
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